The study aims to assess the safety, efficacy and device performance of the Venus-PowerX in severe aortic stenosis patients.
The Phase I trial aims to determine maximum tolerated dose, evaluate pharmacokinetics, and gather preliminary efficacy data.
Lu AH69593 is currently being studied in a Phase Ib clinical trial focused on patients with narcolepsy.
AFTX-201 is an investigational gene therapy delivered through a single intravenous infusion.
